RAMM Pharma (XCNQ:RAMM) Ending Cash Position: C$0.12 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is RAMM Pharma Ending Cash Position?

RAMM Pharma XCNQ:RAMM Ending Cash Position is C$0.12 Mil as of Apr. 2026. The stock has 4 warning signs investors should review.

RAMM Pharma's Ending Cash Position for the quarter that ended in Apr. 2026 was C$0.12 Mil.

RAMM Pharma's quarterly Ending Cash Position increased from Oct. 2025 (C$0.80 Mil) to Jan. 2026 (C$0.99 Mil) but then declined from Jan. 2026 (C$0.99 Mil) to Apr. 2026 (C$0.12 Mil).

RAMM Pharma's annual Ending Cash Position declined from Oct. 2023 (C$5.12 Mil) to Oct. 2024 (C$0.81 Mil) and declined from Oct. 2024 (C$0.81 Mil) to Oct. 2025 (C$0.80 Mil).

RAMM Pharma Ending Cash Position Related Terms

RAMM Pharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for RAMM Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RAMM Pharma Ending Cash Position Chart

RAMM Pharma Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Ending Cash Position
Get a 7-Day Free Trial 17.16 9.77 5.12 0.81 0.80

RAMM Pharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.53 0.80 0.99 0.12

RAMM Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

RAMM Pharma's Ending Cash Position for the fiscal year that ended in Oct. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.814+-0.01
=0.80

RAMM Pharma's Ending Cash Position for the quarter that ended in Apr. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.985+-0.865
=0.12

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of C$0.12 Mil mean?
RAMM Pharma (XCNQ:RAMM) has a Ending Cash Position of C$0.12 Mil as of Apr. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on RAMM Pharma and its competitors.
Is RAMM Pharma's Ending Cash Position too high?
RAMM Pharma's current Ending Cash Position is C$0.12 Mil.
How does RAMM Pharma's Ending Cash Position compare to ZTS?
RAMM Pharma's Ending Cash Position of C$0.12 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on RAMM Pharma and its competitors. RAMM Pharma's current Ending Cash Position is C$0.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RAMM Pharma stock overvalued right now?
Based on GuruFocus' analysis, RAMM Pharma (XCNQ:RAMM) is currently considered Fairly Valued. The stock's GF Value™ is C$0.01, compared to a current price of C$0.01 — trading right at its estimated fair value. The current Ending Cash Position is C$0.12 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For RAMM Pharma (XCNQ:RAMM), the current Ending Cash Position is C$0.12 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RAMM Pharma Business Description

Address 82 Richmond Street E, Toronto, ON, CAN, M5C 1P1
RAMM Pharma Corp is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. The group generates revenue from the sale of medical devices and consumables, the sale of pharmaceutical products, and sale of cosmetics. Geographically, it derives a majority of its revenue from Uruguay.